Passive immunization with Pneumovax® 23 and pneumolysin in combination with vancomycin for pneumococcal endophthalmitis

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Sanders, Melissa E ^a   Taylor, Sidney ^a   Tullos, Nathan ^a   Norcross, Erin W ^a   Moore, Quincy C ^a   Thompson, Hilary ^b   King, Lauren B ^a   Marquart, Mary E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bacterial endophthalmitis; Capsule; Pneumolysin; Streptococcus pneumoniae; Vaccination

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; PNEUMOCOCCUS VACCINE; STREPTOLYSIN; VANCOMYCIN;

ANIMAL; ARTICLE; BACTERIAL COUNT; DISEASE MODEL; DRUG EFFECT; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; METHODOLOGY; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTION; RABBIT; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; IMMUNIZATION, PASSIVE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RABBITS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VANCOMYCIN;

MLCS; MLOWN;

EID: 84874799124     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-8     Document Type: Article

References (46)

1. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Ortqvist A, Hedlund J, Kalin M, Semin Respir Crit Care Med 2005 26 563 574 10.1055/s-2005-925523 16388428 (Pubitemid 43063071)
2. Bacterial meningitis in the United States in 1995. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, Lefkowitz L, Perkins BA, New Engl J Med 1997 337 970 976 10.1056/NEJM199710023371404 9395430 (Pubitemid 27425953)
3. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Overturf GD, American Academy of Pediatrics, Committee on Infectious Diseases, Pediatrics 2000 106 367 376 10.1542/peds.106.2.367 10920170 (Pubitemid 30636414)
4. The innate immune response to pneumococcal lung infection: the untold story. Kadioglu A, Andrew P, Trends Immunol 2004 25 143 149 10.1016/j.it.2003. 12.006 15036042 (Pubitemid 38249488)
5. Pathogenesis of gram-positive bacterial endophthalmitis. Callegan MC, Booth MC, Jett BD, Gilmore MS, Infect Immun 1999 67 3348 3356 10377112 (Pubitemid 29291502)
6. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Callegan MC, Engelbert M, Parke DW II, Jett BD, Gilmore MS, Clin Microbiol Rev 2002 15 111 124 10.1128/CMR.15.1.111-124.2002 11781270 (Pubitemid 34052585)
7. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF, Am J Ophthalmol 1996 122 1 17 8659579 (Pubitemid 26230889)
8. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC, Arch Ophthalmol 2005 123 341 346 10.1001/archopht.123.3.341 15767476 (Pubitemid 41007578)
9. Streptococcus pneumoniae endophthalmitis: a study of 36 cases with special reference to antibiotic resistance and treatment options. Soriano F, Perez-Trallero E, Pallares R, Meseguer MA, Fleites A, Gene A, Gonzalez A, Linares J, Esteban J, Baquero F, Valdes E, Munoz-Almagro C, Clin Microbiol Infec 2006 12 519 526 10.1111/j.1469-0691.2006.01418.x
10. Endophthalmitis caused by Streptococcus pneumoniae. Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Corey RP, Miller D, Am J Ophthalmol 2004 138 231 236 10.1016/j.ajo.2004.03.008 15289132 (Pubitemid 39037427)
11. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. Johnson S, Rubin L, Romero-Steiner S, Dykes J, Pais L, Rizvi A, Ades E, Carlone G, J Infect Dis 1999 180 133 140 10.1086/314845 10353871 (Pubitemid 29293927)
12. Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Kadioglu A, Taylor S, Iannelli F, Pozzi G, Mitchell TJ, Andrew PW, Infect Immun 2002 70 2886 2890 10.1128/IAI.70.6.2886-2890.2002 12010976 (Pubitemid 34564145)
13. Recurrent endocarditis caused by Streptococcus pneumoniae. Lindberg J, Fangel S, Scand J Infect Dis 1999 31 409 410 10.1080/00365549950163888 10528883 (Pubitemid 29454301)
14. Genetic bases and medical relevance of capsular polysaccharide biosynthesis in pathogenic streptococci. Llull D, Lopez R, Garcia E, Curr Mol Med 2001 1 475 491 10.2174/1566524013363618 11899092 (Pubitemid 33772954)
15. Severe pneumococcal infections: virulence aspects. Varon E, Arch Pediatr 2001 8 Suppl 4 752s 756s 11582923
16. Requirement for capsule in colonization by Streptococcus pneumoniae. Magee AD, Yother J, Infect Immun 2001 69 3755 3761 10.1128/IAI.69.6.3755-3761. 2001 11349040 (Pubitemid 32493294)
17. Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the Advisory Committee on Immunization Practices (ACIP). Nuorti JP, Whitney CG, MMWR Recomm Rep 2010 59 1 18 21160459
18. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. Robbins JB, Austrian R, Lee C-J, Rastogi SC, Schiffman G, Henrichsen J, Makela PH, Broome CV, Facklam RR, Tiesjema RH, Parke JC, J Infect Dis 1983 148 1136 1159 10.1093/infdis/148.6.1136 6361173 (Pubitemid 14206325)
19. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA, on behalf of the 004 Study Group, Pediatrics 2010 126 493 e505 10.1542/peds.2009-3027 20732948
20. Essential role for CD40 ligand interactions in T lymphocyte-mediated modulation of the murine immune response to pneumococcal capsular polysaccharides. Jeurissen A, Wuyts M, Kasran A, Ramdien-Murli S, Boon L, Ceuppens JL, Bossuyt X, J Immunol 2002 168 2773 2781 11884445 (Pubitemid 34211656)
21. The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis. Sanders M, Norcross EW, Robertson ZM, Moore QC III, Fratkin J, Marquart ME, Invest Ophthalmol Vis Sci 2011 52 865 872 10.1167/iovs.10-5513 21051708
22. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Tweten RK, Infect Immun 2005 73 6199 6209 10.1128/IAI.73.10.6199-6209. 2005 16177291 (Pubitemid 41368781)
23. Structure and molecular mechanism of a functional form of pneumolysin: a cholesterol-dependent cytolysin from Streptococcus pneumoniae. Kelly S, Jedrzejas M, J Struct Biol 2000 132 72 81 10.1006/jsbi.2000.4308 11121308 (Pubitemid 32095238)
24. Essential role of domain 4 of pneumolysin from Streptococcus pneumoniae in cytolytic activity as determined by truncated proteins. Baba H, Kawamura I, Kohda C, Nomura T, Ito Y, Kimoto T, Watanabe I, Ichiyama S, Mitsuyama M, Biochem Biophys Res Commun 2001 281 37 44 10.1006/bbrc.2001.4297 11178957 (Pubitemid 32924396)
25. Structural analysis of the protein/lipid complexes associated with pore formation by the bacterial toxin pneumolysin. Bonev BB, Gilbert RJC, Andrew PW, Byron O, Watts A, J Biol Chem 2001 276 5714 5719 10.1074/jbc.M005126200 11076935
26. Implication of pneumolysin as a virulence factor in Streptococcus pneumoniae endophthalmitis. Ng EW, Samiy N, Rubins JB, Cousins FV, Ruoff KL, Baker AS, D'Amico DJ, Retina 1997 17 521 529 9428015 (Pubitemid 28032434)
27. Contribution of pneumolysin and autolysin to the pathogenesis of experimental pneumococcal endophthalmitis. Ng EW, Costa JR, Samiy N, Ruoff KL, Connolly E, Cousins FV, D'Amico DJ, Retina 2002 22 622 632 10.1097/00006982- 200210000-00014 12441729 (Pubitemid 35176078)
28. Immunization with pneumolysin protects against both retinal and global damage caused by Streptococcus pneumoniae endophthalmitis. Sanders M, Norcross E, Moore Q, Fratkin J, Thompson H, Marquart M, J Ocul Pharmacol Ther 2010 26 571 577 10.1089/jop.2010.0077 21034245
29. Active immunization with pneumolysin versus 23-valent polysaccharide vaccine for Streptococcus pneumoniae keratitis. Norcross E, Sanders ME, Moore Q, Taylor S, Tullos N, Caston R, Dixon S, Nahm M, Burton R, Thompson H, McDaniel L, Marquart M, Invest Ophthalmol Vis Sci 2011 52 9232 9243 10.1167/iovs.10-6968 22039231
30. THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae. Thornton J, McDaniel LS, Infect Immun 2005 73 6493 6498 10.1128/IAI.73.10.6493-6498.2005 16177322 (Pubitemid 41368812)
31. Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Zhang Q, Choo S, Finn A, Infect Immun 2002 70 5363 5369 10.1128/IAI.70.10.5363-5369.2002 12228260
32. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. Rodriguez-Barradas MC, Musher DM, Lahart C, Lacke C, Groover J, Watson D, Baughn R, Cate T, Crofoot G, J Infect Dis 1992 165 553 556 10.1093/infdis/165.3.553 1347058
33. Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model. Callegan MC, Jett BD, Hancock LE, Gilmore MS, Infect Immun 1999 67 3357 3366 10377113 (Pubitemid 29291503)
34. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J, J Antimicrob Chemother 2006 58 117 124 10.1093/jac/dkl173 16670109 (Pubitemid 44294995)
35. Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. Hobden JA, Hill JM, Engel LS, O'Callaghan RJ, Antimicrob Agents Chemother 1993 37 1856 1859 10.1128/AAC.37.9.1856 8239596 (Pubitemid 23265542)
36. Monographs on statistics and applied probability 41. Crowder M, Hand DJ, Analysis of repeated measures Boca Raton: Chapman & Hall/CRC 1 1990 268
37. The Efficiency of Simulation-Based Multiple Comparisons. Edwards DBJ, Biometrics 1987 43 913 928 10.2307/2531545 3427176 (Pubitemid 18016777)
38. DJ S, Handbook of Parametric and Nonparametric Statistical Procedures Boca Raton: Chapman & Hall/CRC 2000
39. Anaphylatoxin levels in human vitreous humor. Mondino B, Sidikaro Y, Sumner H, Invest Ophthalmol Vis Sci 1988 29 1195 1198 3262096
40. Ocular blood flow and vascular permeability in endotoxin-induced inflammation. Green K, Paterson C, Cheeks L, Slagle T, Jay W, Aziz M, Ophthalmic Res 1990 22 287 294 10.1159/000267037 2090983 (Pubitemid 20383300)
41. Differential expression of the complement regulatory proteins in the human eye. Bora N, Gobleman C, Atkinson J, Pepose J, Kaplan H, Invest Ophthalmol Vis Sci 1993 34 3579 3584 7505007 (Pubitemid 24011995)
42. Limitations of Pneumovax(R) as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay. Huo Z, Miles J, Riches P, Harris T, Ann Clin Biochem 2002 39 398 403 10.1258/ 000456302760042164 12117444 (Pubitemid 34743642)
43. Human anti-pneumococci antibody produced by an Epstein Barr virus (EBV)- immortalized cell line. Steinitz M, Tamir S, Goldfarb A, J Immunol 1984 132 877 882 6317751 (Pubitemid 14183692)
44. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Benz M, Scott I, Flynn H, Unonius N, Miller D, Am J Ophthalmol 2004 137 38 42 10.1016/S0002-9394(03)00896-1 14700642 (Pubitemid 38045185)
45. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Aaberg T, Flynn H, Schiffman J, Newton J, Ophthalmology 1998 105 1004 1010 10.1016/S0161-6420(98)96000-6 9627649 (Pubitemid 28268323)
46. Prophylaxis against infection in cataract surgery: a survey of routine practice. Ang G, Barras C, Eur J Ophthalmol 2006 16 394 400 16761240 (Pubitemid 44049281)